About Biopharmx (NYSEAMERICAN:BPMX)
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:BPMX
CUSIPN/A
Phone+1-650-8895020
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-20,633.33%
Return on EquityN/A
Return on Assets-387.79%
Miscellaneous
EmployeesN/A
Outstanding Shares190,000,000
Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions
What is Biopharmx's stock symbol?
Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
How were Biopharmx's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Wednesday, September, 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.06). The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. View Biopharmx's Earnings History.
When is Biopharmx's next earnings date?
What price target have analysts set for BPMX?
3 brokers have issued 12 month price objectives for Biopharmx's stock. Their forecasts range from $1.50 to $3.00. On average, they anticipate Biopharmx's share price to reach $2.50 in the next twelve months. View Analyst Ratings for Biopharmx.
Are investors shorting Biopharmx?
Biopharmx saw a drop in short interest during the month of March. As of March 29th, there was short interest totalling 12,116,761 shares, a drop of 0.1% from the March 15th total of 12,130,469 shares. Based on an average daily trading volume, of 11,538,273 shares, the days-to-cover ratio is currently 1.1 days. Currently, 7.3% of the company's stock are sold short.
Who are some of Biopharmx's key competitors?
Some companies that are related to Biopharmx include Contango Oil & Gas (MCF), Unique Fabricating (UFAB), Transatlantic Petroleum (TAT), Bovie Medical (BVX), CPI Aerostructures (CVU), Vista Gold (VGZ), Globalscape (GSB), Acme United (ACU), UQM Technologies (UQM), McClatchy (MNI), eMagin (EMAN), OncoCyte (OCX), Avino Silver & Gold Mines (ASM), Plymouth Industrial Reit (PLYM), Navidea Biopharmaceuticals (NAVB), Wireless Telecom Group (WTT), General Moly (GMO) and NovaBay Pharmaceuticals (NBY).
Who are Biopharmx's key executives?
Biopharmx's management team includes the folowing people:
- James R. Pekarsky, Chairman of the Board, Chief Executive Officer (Age 55)
- Anja B. Krammer, President, Director (Age 47)
- Gregory David Kitchener, Chief Financial Officer, Executive Vice President - Finance
- Kin F. Chan Ph.D., Executive Vice President - Research & Development (Age 41)
- AnnaMarie Daniels, Executive Vice President - Clinical and Regulatory Affairs
- Stephen Morlock, Independent Director (Age 61)
- Ping Wang, Independent Director (Age 38)
Has Biopharmx been receiving favorable news coverage?
News stories about BPMX stock have trended somewhat positive on Sunday, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biopharmx earned a media sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Biopharmx?
Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biopharmx's stock price today?
One share of BPMX stock can currently be purchased for approximately $0.2226.
How big of a company is Biopharmx?
Biopharmx has a market capitalization of $45.42 million.
How can I contact Biopharmx?
Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx (BPMX)
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biopharmx (NYSEAMERICAN:BPMX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Biopharmx in the last 12 months. Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 1,023.09%. The high price target for BPMX is $3.00 and the low price target for BPMX is $1.50. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.50 | $2.50 | $2.50 | $2.50 |
| Price Target Upside: | 1,023.09% upside | 2,172.73% upside | 2,172.73% upside | 777.19% upside |
Biopharmx (NYSEAMERICAN:BPMX) Consensus Price Target History
Biopharmx (NYSEAMERICAN:BPMX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 12/8/2017 | Maxim Group | Reiterated Rating | Buy | $1.50 |  |
| 9/19/2017 | HC Wainwright | Reiterated Rating | Buy | $3.00 | |
| 6/3/2017 | Roth Capital | Set Price Target | Buy | $3.00 | |
(Data available from 4/22/2016 forward)
Biopharmx (NYSEAMERICAN:BPMX) Earnings History and Estimates Chart
Biopharmx (NYSEAMERICAN BPMX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/26/2018 | | | | | | | | |
| 12/7/2017 | Q3 2018 | ($0.05) | ($0.05) | $0.03 million | $0.02 million | View | N/A | |
| 9/13/2017 | Q2 2018 | ($0.06) | ($0.06) | $0.02 million | $0.02 million | View | N/A | |
| 6/13/2017 | Q1 2018 | ($0.07) | ($0.07) | $0.03 million | $0.02 million | View | N/A | |
| 3/23/2017 | Q4 2017 | ($0.09) | ($0.09) | $0.04 million | $0.02 million | View | N/A | |
| 12/13/2016 | Q3 2017 | ($0.15) | ($0.13) | $0.03 million | $0.03 million | View | N/A | |
| 9/12/2016 | Q2 2017 | ($0.17) | ($0.18) | $0.07 million | $0.02 million | View | N/A | |
| 6/14/2016 | Q117 | ($0.17) | ($0.16) | $0.09 million | $0.03 million | View | Listen | |
| 4/26/2016 | Q416 | ($0.17) | ($0.18) | $0.05 million | $0.04 million | View | Listen | |
| 12/14/2015 | Q316 | ($0.19) | ($0.17) | | $0.02 million | View | N/A | |
| 9/14/2015 | Q216 | ($0.29) | ($0.22) | | $0.01 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Biopharmx (NYSEAMERICAN:BPMX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biopharmx (NYSEAMERICAN BPMX) Insider Trading and Institutional Ownership History
Biopharmx (NYSEAMERICAN BPMX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/7/2018 | Vivo Capital Viii, Llc | Major Shareholder | Sell | 2,000,000 | $0.36 | $720,000.00 | | |
| 11/24/2017 | Stephen Morlock | Director | Buy | 330,000 | $0.15 | $49,500.00 | | |
| 11/9/2017 | Vivo Capital Viii, Llc | Major Shareholder | Sell | 296,394 | $0.20 | $59,278.80 | | |
| 8/1/2017 | Franklin Resources Inc | Major Shareholder | Buy | 250,000 | $0.34 | $85,000.00 | | |
| 4/28/2017 | Vivo Capital Fund Viii, L.P. | Major Shareholder | Buy | 1,282,052 | $0.78 | $1,000,000.56 | | |
| 11/28/2016 | Stephen Morlock | Director | Buy | 428,571 | $0.35 | $149,999.85 | 543,956 | |
| 8/15/2016 | Franklin Resources Inc | Major Shareholder | Buy | 484,615 | $0.65 | $314,999.75 | | |
| 3/29/2016 | Franklin Resources Inc | Major Shareholder | Buy | 540,000 | $1.20 | $648,000.00 | | |
| 1/14/2016 | Stephen Morlock | Director | Buy | 12,000 | $1.52 | $18,240.00 | | |
| 1/12/2016 | Stephen Morlock | Director | Buy | 6,000 | $1.53 | $9,180.00 | | |
| 1/7/2016 | Stephen Morlock | Director | Buy | 5,000 | $1.47 | $7,350.00 | | |
| 10/15/2015 | Stephen Morlock | Director | Buy | 5,000 | $1.24 | $6,200.00 | | |
| 10/9/2015 | Stephen Morlock | Director | Buy | 3,000 | $1.21 | $3,630.00 | 223,071 | |
(Data available from 1/1/2013 forward)
Biopharmx (NYSEAMERICAN BPMX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Biopharmx Corp (BPMX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - April 12 at 2:43 AM |
| Short Interest in Biopharmx Corp (BPMX) Expands By 16.2%
www.americanbankingnews.com - March 26 at 6:54 PM |
 | BioPharmX (BPMX) Awarded US Patent Protection for Novel Tetracycline-class Topical Drug Compositions - StreetInsider.com
www.streetinsider.com - March 21 at 8:48 AM |
 | Today’s Research Reports on Trending Tickers: BioPharmX and MediWound
finance.yahoo.com - March 21 at 8:48 AM |
| U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions
finance.yahoo.com - March 20 at 5:18 PM |
| BioPharmX to Present at Oppenheimer's 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 7:07 PM |
| Biopharmx (BPMX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:16 AM |
| Biopharmx Corp (BPMX) Short Interest Update
www.americanbankingnews.com - March 10 at 1:48 AM |
| Biopharmx Corp (BPMX) Major Shareholder Sells $720,000.00 in Stock
www.americanbankingnews.com - March 9 at 6:14 PM |
| Loss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To Breakeven
finance.yahoo.com - March 7 at 6:35 PM |
| BioPharmX to Present at 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 5:50 PM |
| Short Interest in Biopharmx Corp (BPMX) Grows By 37.3%
www.americanbankingnews.com - February 27 at 5:58 PM |
| Biopharmx Corp (BPMX) Sees Large Increase in Short Interest
www.americanbankingnews.com - February 9 at 8:28 PM |
| BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month
finance.yahoo.com - January 12 at 9:17 AM |
| Short Interest in Biopharmx Corp (BPMX) Grows By 2.3%
www.americanbankingnews.com - January 10 at 5:38 PM |
| Biopharmx Corp (BPMX) Short Interest Up 21.9% in December
www.americanbankingnews.com - December 27 at 6:40 PM |
| How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead?
finance.yahoo.com - December 25 at 6:33 PM |
| ETFs with exposure to BioPharmX Corp. : December 14, 2017
finance.yahoo.com - December 14 at 5:25 PM |
| BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017
finance.yahoo.com - December 13 at 10:19 AM |
| Biopharmx (BPMX) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - December 8 at 10:02 AM |
| BioPharmX Reports Third Quarter 2018 Financial Results
finance.yahoo.com - December 7 at 5:14 PM |
| BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Treatment of Acne at ASCB 2017
finance.yahoo.com - December 4 at 9:58 AM |
| Biopharmx Corp (BPMX) Director Stephen Morlock Acquires 330,000 Shares
www.americanbankingnews.com - November 27 at 8:40 PM |
 | BRIEF-BioPharmX Corp announces pricing of public offering
www.reuters.com - November 21 at 8:23 PM |
 | Report: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, Dean
www.nasdaq.com - November 16 at 12:08 PM |
| Report: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX — Future Expectations, Projections Moving into 2018
finance.yahoo.com - November 16 at 12:08 PM |
Biopharmx (NYSEAMERICAN:BPMX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Biopharmx (NYSEAMERICAN BPMX) Stock Chart for Sunday, April, 22, 2018
Loading chart…
